NCT05937321Active, not recruiting
National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring With Data Sharing in Older Adults With Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.
NIDDK Share Plus: Continuous Glucose Monitoring With Data Sharing in Older Adults With T1D and Their Care Partners
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to test the Share plus intervention aimed at improving the use of data sharing between people with diabetes and their care partners in order to maximize the benefits of continuous glucose monitoring. Hypothesis: Compared to the control group, persons with diabetes enrolled in the Share plus intervention group will experience clinically significant improvements in time-in-range (TIR) (\>5%) at 12- and 24-weeks into the study, and improvement on diabetes distress. Care partners enrolled in the Share plus intervention group will experience lower diabetes distress at 12- and 24-weeks into the study.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 168 (actual)
- First submitted
- 21 Jun 2023
- Start date
- 2 Nov 2023
- Primary completion date
- 20 Apr 2026
- Lead sponsor
- University of Utah
- Diseases
- Type 1 diabetes
- NCT number
- NCT05937321
What you commit to
- Study type: Interventional
- Participants enrolled: 168
- From 2 Nov 2023 to the primary completion date, 20 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Extreme visual or hearing impairment that would hinder the ability to use CGM
- The presence of a significant medical or psychiatric condition or use of a medication that in the investigator's judgment may affect the completion of any aspect of the protocol.
- Clinical diagnosis of moderate or severe dementia
- Inpatient psychiatric treatment in the past six months
- Cognitive impairment or dementia
- Medical condition that will make it inappropriate or unsafe to fulfill the role of a CP
Lab values
- Stage 4 or 5 renal disease or most recent Glomerular filtration rate (GFR) \<30 ml/min/m2 from a local lab within the past six months
Other
- Life expectancy estimated at \< 1 year
- Participation in an intervention study in the past six weeks
- Montreal Cognitive Assessment Score \< 19
Who the study is looking for
- 60 + years of age
- Type 1 Diabetes Diagnosis
- HbA1c no greater than 11.0%
- Currently using continuous glucose monitoring
- Able to manage diabetes with respect to insulin administration and glucose monitoring (which may include assistance from a care partner
- ≥18 years of age
- Participant understands the study protocol and agrees to comply with it
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Utah College of Nursing Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.